Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
RBA.TO 0.66CEG -5.66AVGO -2.75EWW -0.68JCI -2.62NVDA -10.43IMO.TO -1.89DPM.TO -2.43
Novo-Nordisk (NVO)

NYSE:NVO

Novo-Nordisk (NVO)

45.61
-0.65 (1.41%)
as of Aug 28, 2026, 8:00:00 pm Market Open.
268 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 28, 2026, 12:00 am

This summary was created by AI, based on 33 opinions in the last 12 months.

Novo Nordisk (NVO) has seen a decline in its market position, particularly in the competitive landscape for GLP-1 drugs where Eli Lilly (LLY) is dominating. Many analysts express concerns about NVO losing market share and not capitalizing effectively on its weight-loss drug offerings. While NVO retains a high-quality franchise in diabetes management and a relatively low price-to-earnings (PE) ratio of 11x, its future growth potential appears clouded by increasing competition and pricing pressures. Recent insider buying offers a glimmer of optimism, but overall sentiment remains cautious, with expectations of only modest earnings growth. The stock's technical chart shows downward trends, leading many experts to recommend patience in assessing recovery potential before committing to long-term investments.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Novo-Nordisk(NVO)

Feb 23, 2006
Past Top pick. Insulin demain is growing over the next 20 years. It's still a long term investment.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$58.16

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Nov 03, 2005
Manufactures insulin. Human insulin is in huge demand and they control the market. Good earnings last quarter. Good price.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$52.53

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Aug 03, 2005
The growth in cases of diabetes in the next 20 years is expected to double from 3 to 6 hundred million globally. The stock had fallen from $58 to the low $50's because their drug was going to be delayed. Stock is now getting interesting.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$54.70

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Novo-Nordisk(NVO)

Jun 08, 2004
(A top pick Dec 1/03. Up 30%.) The cases of diabetics is expected to double.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$47.89

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Dec 11, 2003
In pharmaceuticals, they devote most money per revenue into R&D. Demographically, feels that China and India will be strong future markets.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$37.33

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Aug 22, 2001
Takeover target. Diabetes is growing. Expects 10/15% growth over time.
Photo of David DriscollDavid DriscollUnlock Rating
$45.26

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Aug 07, 2001
Great company. Will do well.
Photo of Arthur HeinmaaArthur HeinmaaUnlock Rating
$43.41

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Jun 22, 2001
Trading at FMV. 33% growth in diabetes.
Photo of David DriscollDavid DriscollUnlock Rating
$44.43

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Jun 04, 2001
Just split. Growing 40% in sales. Growth is in the 30/40% range.
Photo of David DriscollDavid DriscollUnlock Rating
$42.66

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Mar 27, 2001
Bullet proof portfolio-mid caps (35%)
Photo of David DriscollDavid DriscollUnlock Rating
$103.18

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Novo-Nordisk(NVO)

Feb 28, 2001
Good earnings. Growing at 50% a year.
Photo of David DriscollDavid DriscollUnlock Rating
$99.50

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
BUY

Novo-Nordisk(NVO)

Nov 06, 2000
Held their own in market drop. Good price now
Photo of David DriscollDavid DriscollUnlock Rating
$101.00

Stock price when the opinion was issued

$45.61

As of Aug 28, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 207 of 207 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PFE -0.06$27.96
MDT 1.26$91.23
BBY -1.12$82.44
TTWO 2.39$235.39
MDT 1.26$91.23

Today's Top Picks

RBA.TO 0.66$119.68
CEG -5.66$276.75
AVGO -2.75$368.79
EWW -0.68$76.48
JCI -2.62$139.59

Popular Articles

Latest Sell Signals

EIF.TO -1.16$121.64
FTS.TO 0$76.06
ENB.TO 0.48$69.76
MCD 4.94$265
IBM -3.2$235.59

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like